Alisertib Plus Paclitaxel Shows Promise for Patients With SCLC
Alisertib showed antitumor activity in preclinical in vivo small cell lung cancer (SCLC) models.
Alisertib showed antitumor activity in preclinical in vivo small cell lung cancer (SCLC) models.
Next-generation sequencing (NGS) of circulating DNA (ctDNA) could be used to identify emergent resistance mutations.
Tumor genomes in tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations that are associated with poor outcomes.